Navigation Links
Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
Date:7/29/2008

CAMBRIDGE, Mass., July 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the second quarter ended June 30, 2008. At June 30, 2008, Idenix's cash, cash equivalents and marketable securities totaled $80.6 million.

2008 Year-to-Date Business Highlights

-- Idenix has reported positive data from an ongoing phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1. Patients receiving once-daily IDX899 achieved a mean plasma viral load reduction of approximately 1.8 log(10) after seven days of treatment in each of the 800 mg, 400 mg and 200 mg dosing cohorts. Patients receiving placebo had a 0.05 log(10) viral load increase over the same treatment period. No treatment-related serious adverse events were reported for any of the patients receiving IDX899 and no patients discontinued the study. Based on the potent antiviral activity of IDX899 observed to date, the study was recently amended to also evaluate a 100 mg/day dose.

-- Idenix has submitted an investigational new drug (IND) application for IDX184, a once-daily, oral nucleotide prodrug candidate for the treatment of chronic hepatitis C, to the United States Food and Drug Administration (FDA) and has initiated a phase I single dose escalation study in healthy volunteers. IDX184 has demonstrated HCV antiviral activity in both in vitro and in vivo preclinical models.

-- Idenix has continued to make progress in its preclinical HCV discovery effort. Clinical candidates from both its HCV pro
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
2. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
3. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
5. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
6. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
7. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
8. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
9. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
10. Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Last week, Representatives ... Butterfield (D-NC) took a bold bipartisan step ... introducing the OPEN Act. Original co-sponsors of the ... The Act will incentivize drug makers and innovators ... diseases and pediatric cancers, which opens the door ...
(Date:11/24/2014)... BELLINGHAM, Washington, USA (PRWEB) November 23, 2014 ... the dynamic field of optics and photonics is now available ... no or very low cost. SPIE, the international society ... making access to the complete SPIE Digital Library ... a subsidized price. , “Light-based technologies are integral to all ...
(Date:11/24/2014)... 24, 2014  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today ... Ltd.,  Case No. 3:13-cv-03494-M and  Spherix v. Uniden ... in the United States District Court for the ... On November 21, 2014 the ...
(Date:11/22/2014)... 21, 2014 During his lifetime Richard ... need to surround himself with great people and take ... his friends often marveled at his extraordinarily courageous attitude ... life and -- even with his death impending—that’s how ... disease that would ultimately take his life. , Carrying ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3
... Neurognostics, Inc ., a Wisconsin company specializing ... announced today that the Food and Drug Administration (FDA) ... its trademarked MindState fDAD. MindState fDAD had previously ... acquisition device. The Special 510(k) allows Neurognostics to enhance ...
... Merge eMed , a Merge Healthcare ... company, today announced the release of Cedara I-ReadMammo ... mammography workstation software product is designed to help ... in adopting digital mammography. , ,I-ReadMammo was ...
... happen. In a country that invented take out food, that is ... is perpetually in motion, it was inevitable that work and indeed ... ten years, the place where knowledge work happens has shifted from ... deck, in a subway car, walking down the street or of ...
Cached Biology Technology:Who moved the workplace? 2Who moved the workplace? 3Who moved the workplace? 4
(Date:11/4/2014)... In nature, the right amount of death at the ... density, according to new research that could help in ... wildlife stocks. , In a paper in the journal ... University researcher and European colleagues conclude that the kind ... a loss of individuals, or mortality, depends on the ...
(Date:11/4/2014)... examining only marketing directed at children on the ... found that the majority of black, middle-income and ... tactics. , Authored by Arizona State University researcher ... the first to examine the use of child-directed ... food restaurants and its relationship to demographics. It ...
(Date:11/4/2014)... , Nov. 4, 2014   Neurotechnology ... today announced that the latest version of its ... the Ongoing MINEX evaluation organized by ... fingerprint algorithms using the INCITS 378 fingerprint standard ... requirement in public tenders in the ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3
... technology that uses "green" chemistry to help microbes break ... has earned kudos from the editors of Environmental Protection ... the Year. , The technology, which was invented by ... and licensed and manufactured by EOS Remediation, LLC, a ...
... , This release is available in French ... has played a role in the development of the many ... dart frog, according to a study that will be published ... University of Montreal biologist Mathieu Chouteau. The researcher,s methodology was ...
... James Wilkinson at the University of Southampton,s Optoelectronics ... Council (ERC) Advanced Grant to realise tools for ... analysis in water pollution and food safety. , ... biophotonics research in near- to mid-infra-red devices. ...
Cached Biology News:Predators drive the evolution of poison dart frogs' skin patterns 2
More cell-permeant than acridine orange....
Anti-rat Ig HRP detection kit...
One bottle containing 30 ml of protein solution and 0.1% sodium azide....
Used in May-Grunwald Giemsa stain....
Biology Products: